Our view on Resmed (RMD) is different to the other brokers. Of the 8 covering it, 7 rate it as a buy, with one neutral. When everyone is bullish, the contrarian trade normally wins out, doesn't it? You can read our views on RMD via the following link: (VIEW LINK) For a copy of the full report containing other trading and investment ideas, visit our website (VIEW LINK)
Michael Gable is managing director of Fairmont Equities. We are a small boutique advisory that uniquely combines both fundamental and technical analysis. As a result, our analysis is featured regularly in the finance media such as the Australian...
No areas of expertise